Healthcare Jun 23, 2022 10:27 AM (GMT+8) · EqualOcean
On June 22, the s-217622 emergency authorization application submitted by Shionogi based on phase II data was suspended by Japan PMDA, saying that "more careful discussion is required". S-217622 is an oral 3CL protease inhibitor jointly developed by Hokkaido University and yannoyi. Its mechanism of action is the same as that of pavlovid, covid-19 approved by Pfizer. In February, yannoyi published partial data of phase IIa of phase ii/iii clinical trial of s-217622. The results showed that compared with the placebo group, the s-217622 group could achieve a rapid decline in virus titer and viral RNA.